AbbVie Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABBV New York 2834 https://www.abbvie.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AbbVie Inc

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy? - Feb 2nd, 2023 3:01 pm
2 Surefire Stocks to Buy in 2023 and Hold for at Least the Next Decade - Feb 2nd, 2023 2:53 pm
3 Ultra-Profitable Businesses to Invest in for the Long Haul - Feb 2nd, 2023 2:00 pm
Merck (MRK) Beats Q4 Earnings and Revenue Estimates - Feb 2nd, 2023 12:55 pm
How Revance Therapeutics, The IBD 50's No. 1 Stock, Is Taking On 'Prestige' Medical Aesthetics - Feb 1st, 2023 6:39 pm
FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high - Feb 1st, 2023 6:32 pm
America’s top-selling drug Humira loses monopoly status - Feb 1st, 2023 5:36 pm
AbbVie Inc. (NYSE:ABBV) is a favorite amongst institutional investors who own 70% - Feb 1st, 2023 11:00 am
3 Juicy Dividend Stocks in Warren Buffett's Secret Portfolio to Buy in February - Feb 1st, 2023 10:55 am
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff - Jan 31st, 2023 9:04 pm
First Humira Biosimilar Price Highlights Cost-Saving Challenges - Jan 31st, 2023 6:07 pm
UPDATE 1-Amgen launches biosimilar version of AbbVie's Humira - Jan 31st, 2023 3:25 pm
15 Largest Ophthalmology Companies in the World - Jan 31st, 2023 2:25 pm
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates - Jan 31st, 2023 1:15 pm
AbbVie's Humira gets a U.S. rival, but costs could stay high - Jan 31st, 2023 11:18 am
Blockbuster AbbVie drug Humira to face competition in US for first time - Jan 31st, 2023 11:00 am
Blockbuster Arthritis Drug Humira Faces Competition From First Lower-Price Copycat in U.S. - Jan 31st, 2023 11:00 am
Amgen launches biosimilar version of AbbVie's Humira - Jan 31st, 2023 11:00 am
'Go big or go home': How a Peninsula biotech looks to win in Humira biosimilar 'feeding frenzy' - Jan 30th, 2023 10:57 pm
AbbVie (ABBV) Stock Moves -0.43%: What You Should Know - Jan 30th, 2023 10:45 pm